Mobia Medical (MOBI) investor relations material

Market opportunity and clinical need

• Stroke is a leading cause of long-term disability in the U.S., with over 9 million ischemic stroke survivors and 800,000 new strokes annually.

• Chronic stroke survivors with moderate-to-severe upper extremity impairment represent a large, underserved population, with an estimated 1 million strong candidates for VivistimⓇ Therapy.

• The serviceable U.S. market for VivistimⓇ Therapy exceeds $30 billion, with a $1.5 billion annual addressable market.

Product overview and differentiation

• VivistimⓇ is the first and only FDA-approved, clinically validated solution for chronic ischemic stroke survivors with upper limb impairment.

• The system uses paired vagus nerve stimulation (VNS) to enhance neuroplasticity and restore hand and arm function.

• Minimally invasive, with unique intellectual property and technical features, VivistimⓇ is supported by a dedicated commercial organization.

Clinical evidence and patient outcomes

• Over 20 publications support VivistimⓇ Therapy, including a pivotal RCT showing 2-3x greater recovery in hand and arm function versus control.

• Long-term data show sustained benefits, with >75% responder rate and significant improvements in daily function and quality of life.

• Real-world outcomes demonstrate transformative impact, with patients regaining key abilities such as handwriting, typing, and self-care.